According to a recent Securities and Exchange Commission (SEC) filing, James C.Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, Inc., sold the company’s 41,434 shares of common stock on January 5, 2026. This sale, conducted under a pre-arranged 10b5-1 trading plan, earned the company a total of $2,534,661.
The Increased Demand For Arrowhead’s Shares
Previously, on January 2nd of this year, the Chief Executive Officer of Arrowhead, Christopher Richard Anzalone, sold 13,187 shares of the company’s common stock, following a 227% return over the past year.
These back-to-back sales occurred amid strong recent performance in the company’s shares, supported by positive business developments
The company’s shares, during recent years, have received significant momentum and have delivered strong returns, caused by the company’s progress in its RNA interference (RNAi) drug pipeline and strategic collaborations.
Anzalone has also been active in the market during the recent months and has executed multiple stock sales, as represented in disclosures. This move, totalling millions of dollars, is part of routine trading and tax-related share disposals tied to equity compensation.
Company Performance And Investor Sentiment
The strong clinical data and strategic partnerships have put Arrowhead’s business in focus. The biotech company, headquartered in Pasadena, California, has made significant advancements in RNAi-based therapeutics and has seen its stock prices increase along with the industry enthusiasm.
Market analysts view the stock sales as a planned selling under a pre-set trading plan rather than larger trades that can generate headlines. This strategic move helps build confidence in the company’s fundamentals.
Arrowhead Makes Significant Shifts In The Market
In recent news, the company has received approval for its triglyceride-lowering drug, REDEMPLO, from Health Canada, and it can now be self-administered at home. REDEMPLO can be used in adults with familial chylomicronemia syndrome (FCS).
Moreover, Piper Sandler raised the price target for Arrowhead to $100 in the scenario of the successful launch of REDEMPLO. RBC Capital also increased the price target to $80 following the effective meetings with Arrowhead’s management. RBC expressed its optimism in the upcoming trial results of Arrowhead’s hypertriglyceridemia candidates.
Bernstein SocGen Group adjusted its price target for Arrowhead to $35, pointing to the potential of the company in treating obesity.
Reports also say that Arrowhead Pharmaceuticals has initiated a Phase 1/2a clinical trial for ARO-MAPT, focusing on tauopathies like Alzheimer’s disease. The trial highlighted the company’s innovative CNS delivery technology, developed to penetrate the blood-brain barrier.
All these recent developments of the company’s ongoing advancements in RNAi give the company an opportunity to make it to the frontline of the market.
What To Expect From Arrowhead Pharmaceuticals?
With all the recent developments from Arrowhead, the investors are keenly watching for further updates on the company’s clinical trials and strategic collaborations, along with insider filings that could influence the market sentiments.
The potential commercial launches of the RNAi therapeutics targeting the difficult-to-treat diseases could gather long-term value for the company’s shares.
